Imagen de Portada

Cyclophosphamide—A promising solution for refractory ICANS

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Manan Vora, Himanshu Gujarathi, Hasmukh Jain, Alok Shetty, Vasundhara Patil, Savan Pandey, M. V. Ramya Kumar, Lingaraj Nayak
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	British Journal of Haematology
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Non‐ ICANS neurological toxicities associated with BCMA‐ directed CAR T‐cell therapy in patients with plasma cell dyscrasia: A systematic review and pooled analysis
por: Manpreet Saini, et al.
Publicado: (2026)

Transient imaging changes accompany ‘spinal ICANS ’ following CAR T‐cell therapy for large B‐cell lymphoma in adults
por: Frederick W. Vonberg, et al.
Publicado: (2025)

Forecasting optimal treatments in relapsed/refractory mature T‐ and NK‐cell lymphomas: A global PETAL Consortium study
por: Mark N. Sorial, et al.
Publicado: (2025)

The bold promise of gene therapy for sickle cell disease
por: Russell E. Ware, et al.
Publicado: (2024)

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T‐cell lymphomas
por: Christina Poh, et al.
Publicado: (2026)

Treatment of refractory/relapsed Diamond–Blackfan anaemia with eltrombopag
por: Brynn B. Duncan, et al.
Publicado: (2024)

The importance of ABO in platelet refractoriness, an often overlooked option
por: Richard Gammon, et al.
Publicado: (2024)

Teclistamab for relapsed refractory multiple myeloma patients on dialysis
por: P. Lebreton, et al.
Publicado: (2024)

Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis
por: Deevyashali Parekh, et al.
Publicado: (2024)

How I treat iron‐refractory iron deficiency anaemia—An expert opinion‐based treatment guidance for children and adults
por: V. Hoving, et al.
Publicado: (2025)

Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies
por: Hind Rafei, et al.
Publicado: (2024)

Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia
por: Tony Marchand, et al.
Publicado: (2024)

Prognostic impact of valemetostat in relapsed/refractory adult T‐cell leukaemia‐lymphoma
por: Takafumi Shichijo, et al.
Publicado: (2025)

Real‐world experience with CAR‐T therapy in relapsed and refractory follicular lymphoma
por: Nicolás Triantafilo, et al.
Publicado: (2025)

Glofitamab in refractory Burkitt lymphoma‐type post‐transplant lymphoproliferative disorder
por: Ho Pui Jeff Lam, et al.
Publicado: (2026)

Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53‐mutant mantle cell lymphoma
por: Manik Uppal, et al.
Publicado: (2025)

Tandem combination of ASCT and CAR T‐cell therapy in highly refractory CNS lymphomas
por: Lydia Montes, et al.
Publicado: (2025)

CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
por: Emil Arjun Kumar, et al.
Publicado: (2024)

Venetoclax‐based non‐intensive combinations for relapsed/refractory acute myeloid leukaemia—Real‐world data from a UK ‐wide programme
por: Henry Wood, et al.
Publicado: (2025)

Retreatment with talquetamab and pomalidomide in triple‐class– BCMA – GPRC5D refractory myeloma
por: Kian J. Rahbari, et al.
Publicado: (2026)

Enitociclib ( VIP152 ), venetoclax and prednisone in relapsed or refractory aggressive non‐Hodgkin lymphoma
por: Max J. Gordon, et al.
Publicado: (2025)

Endothelial activation and stress index ( EASIX ) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment
por: Sergio Rodriguez‐Rodriguez, et al.
Publicado: (2025)

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence
por: Monique A. Hartley‐Brown, et al.
Publicado: (2024)

Two‐year follow‐up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study
por: Yuqin Song, et al.
Publicado: (2025)

Management of relapsed or refractory large B‐cell lymphoma: A British Society for Haematology Guideline
por: Sridhar Chaganti, et al.
Publicado: (2025)

Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series
por: Gráinne Marron, et al.
Publicado: (2026)

Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post‐revumenib therapies
por: Miles Thomas, et al.
Publicado: (2025)

Is universal CAR T‐cell referral absolutely required for transplant‐ineligible patients with primary refractory or early relapsed DLBCL ?
por: Maria Dimou, et al.
Publicado: (2026)

Successful autologous haematopoietic stem cell transplantation in a refractory anti‐myelin‐associated glycoprotein antibody neuropathy
por: Fanny Urbain, et al.
Publicado: (2024)

Successful combined venetoclax to PD‐1 blockade and ruxolitinib for refractory Epstein–Barr virus‐associated haemophagocytic lymphohistiocytosis
por: Yue Song, et al.
Publicado: (2024)

Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single‐centre, retrospective study
por: Yu‐Han Gao, et al.
Publicado: (2024)

Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T‐cell precursor acute lymphoblastic leukaemia
por: Vaibhav Agrawal, et al.
Publicado: (2025)

PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia
por: Jaimal Kothari, et al.
Publicado: (2024)

Efficacy and safety of olverembatinib in adult BCR :: ABL1 ‐positive ALL with T315I mutation or relapsed/refractory disease
por: Weiyang Liu, et al.
Publicado: (2024)

The early and rapid response to daratumumab in children with chronic refractory immune thrombocytopenia from a referral single centre of China
por: Yu Hu, et al.
Publicado: (2024)

Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T‐cell lymphomas: A retrospective single‐centre experience
por: Filippo Bagnoli, et al.
Publicado: (2026)

Successful management of refractory immune‐mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti‐VWF nanobody caplacizumab
por: Roman R. Schimmer, et al.
Publicado: (2024)

Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study
por: Swetha Kambhampati Thiruvengadam, et al.
Publicado: (2025)

T‐cell‐based immunotherapies for human immunodeficiency virus patient with relapsed/refractory multiple myeloma: A success story from our clinic
por: S. Moraru, et al.
Publicado: (2025)

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial
por: Sosana Delimpasi, et al.
Publicado: (2026)